Pharmaceutical company Achaogen received a $5.6 million grant from the U.K.-based Wellcome Trust as part of its Seeding Drug Discovery Initiative. The money will go toward phase one clinical trials of the San Francisco company’s lead drug candidates, aimed at treating bacterial infections that are already resistent to multiple antibiotics.

It last raised funds in 2006, bringing in $26 million in second-round funding from Venrock, Versant Ventures, Domain Associates and Arch Venture Partners.

VentureBeat's mission is to be a digital town square for technical decision-makers to gain knowledge about transformative enterprise technology and transact. Discover our Briefings.